Anti-EGFR and anti-CD3 bispecific antibody and uses thereof
US11396547B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 28, 2017 |
| Grant date | Jul 26, 2022 |
| Priority date | — |
| Expiry date | Mar 9, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
An anti-Epidermal Growth Factor Receptor (EGFR) and anti-Cluster-of-Differentiation (CD3) bispecific antibody and uses thereof are provided. The bispecific antibody can specifically bind to antigen epidermal growth factor receptor (EGFR) on tumor cell surface and antigen CD3 molecule on immune cell surface. The single-chain antibody (ScFv) of an anti-CD3 antibody is located at the C terminal of the constant region of the anti-EGFR antibody. Further provided are a preparation method of the bispecific antibody and clinical applications of the bispecific antibody. The bispecific antibody has high affinity, and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by other overexpression of the EGFR.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.